pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
CAR-T · news · pharmadog
← back to CAR-T
News · CAR-T
190
stories
3d
Novartis details eczema win, autoimmune CAR-T efforts after rocky quarter
endpoints
3d
9 biotechs will cut at least half their California workforces
biospace
3d
Recon: FDA approves drugs for four rare diseases; Pfizer signs $2.6B licensing deal in China for in vivo CAR-T
raps
4d
Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
biopharma dive
4d
Pfizer launches into autoimmune CAR T with China's Starna in up to $2.6B deal
biospace
4d
Pfizer gets into in vivo CAR-T through licensing deal with Starna Therapeutics
endpoints
4d
Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s Starna
fiercebiotech
5d
Researchers may have to ‘revise a lot’ of theories about dementia after uncovering plastics in brain
fiercebiotech
5d
China's $40k CAR-T; Novartis and Biogen strike deals
endpoints
6d
Deaths, failed trials and other recent setbacks in the autoimmune space
biospace
9d
Regeneron posts mid-stage POTS data; Kyverna completes CAR-T filing
endpoints
9d
Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
biospace
9d
Cellectis will shed 70% of workforce as part of in vivo pivot
fiercebiotech
9d
Webinar: Optimizing Cell Therapy Manufacturing Efficiency with Cryopreserved Cells
biospace
10d
Kyverna abandons next-gen autoimmune CAR-T once touted as follow-up to miv-cel
fiercebiotech
13d
Update: FDA investigates Novartis' Zolgensma following 9 cases of tumors in treated patients
biospace
16d
Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma
biospace
17d
Generate CEO sees ‘huge opportunity’ from using Claude to shorten CAR-T cell engines
fiercebiotech
18d
6 potential blockbusters that could pave China’s path to 2030 ambitions
biospace
20d
Cell therapy investment grows as safety events rankle Big Pharma's CAR T autoimmune push
biospace
23d
Gilead CAR-T on partial clinical hold; Agios' PDUFA date pushed back
endpoints
23d
Gilead reveals partial clinical hold on 2 CAR-T cell therapy trials
fiercebiotech
24d
STAT+: Lawmaker wants government watchdog to probe TrumpRx over claims about drug savings
stat
25d
STAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more
stat
25d
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
biospace
25d
STAT+: Missouri AG warns Lilly to stop requiring data from hospitals seeking 340B drug discounts
stat
26d
Artiva to quit autoimmune cell therapy work, cut staff after patient deaths
biopharma dive
26d
Outpace ends an ovarian cancer trial; Incyte data impresses at ESMO
endpoints
26d
STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more
stat
26d
Artiva lays off 94% of staff after deaths and durability sink autoimmune cell therapy
fiercebiotech
← prev
page 1 of 7
next →